| Dr David Lawrence August, MD | |
|
5605 W Eugie Ave Ste 110, Glendale, AZ 85304-1273 | |
| (623) 847-2000 | |
| (623) 847-2001 |
| Full Name | Dr David Lawrence August |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | 5605 W Eugie Ave Ste 110, Glendale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508933847 | NPI | - | NPPES |
| 440895 | Medicaid | AZ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Banner Estrella Medical Center | Phoenix, AZ | Hospital |
| Huhu Kam Memorial Hospital | Sacaton, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner Imaging Services Llc | 1850724386 | 90 |
| Sonoran Radiology Ltd | 3375964505 | 367 |
| Associated Valley Radiologists Ltd | 8325388499 | 41 |
| California Managed Imaging Medical Group Inc | 9436229887 | 88 |
| Gila River Health Care Corporation | 0648174185 | 173 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | Southwest Diagnostic Imaging Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902896236 PECOS PAC ID: 7416946199 Enrollment ID: O20040507001294 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | Associated Valley Radiologists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932683257 PECOS PAC ID: 8325388499 Enrollment ID: O20190327003225 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | Banner Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770139958 PECOS PAC ID: 1850724386 Enrollment ID: O20191213001312 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | Sonoran Radiology Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033745708 PECOS PAC ID: 3375964505 Enrollment ID: O20200526002412 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Entity Name | California Managed Imaging Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821271727 PECOS PAC ID: 9436229887 Enrollment ID: O20220127001824 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Lawrence August, MD 2323 W Rose Garden Ln, Phoenix, AZ 85027-2530 Ph: (602) 521-6252 | Dr David Lawrence August, MD 5605 W Eugie Ave Ste 110, Glendale, AZ 85304-1273 Ph: (623) 847-2000 |
News Archive
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
PharmaTrust, makers of the world's leading remote prescription drug dispensing technology, has signed an agreement with the Ontario Telemedicine Network that will enable OTN's Members, including hospitals, to integrate PharmaTrust's technology into their telemedicine service offering. This new development will expand access to valuable pharmacy services for Ontarians.
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
The Senate Health, Education, Labor and Pensions Committee on Wednesday voted 18-3 to approve a bill (S 558) sponsored by Sen. Pete Domenici (R-N.M.) that would require health insurers to provide the same level of coverage for treatment of mental illnesses and substance abuse as they provide for physical illnesses, CQ Today reports.
› Verified 4 days ago
Dr. Perry S Hiscok, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7111 W Bell Rd, Suite 104, Glendale, AZ 85308 Phone: 623-533-4465 | |
Dr. Murali G Murty, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5810 W Beverly Ln, Glendale, AZ 85306 Phone: 623-312-3000 Fax: 623-312-3060 | |
Dr. Abhinav P Patel, MD Radiology Medicare: Medicare Enrolled Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Phillip M Moeser, MD Radiology Medicare: Medicare Enrolled Practice Location: 5322 W Northern Ave, Southwest Diagnostic Imaging Ltd, Glendale, AZ 85301 Phone: 480-425-5063 Fax: 623-915-6924 | |
Denise J Smith, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5605 W Eugie Ave Ste 110, Glendale, AZ 85304 Phone: 623-847-2000 | |
Patrick R Miller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5810 W Beverly Ln, Glendale, AZ 85306 Phone: 623-312-3000 Fax: 623-312-3060 | |
Dr. Raul Galvez-trevino, M.D., M.P.H. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5605 W Eugie Ave Ste 110, Glendale, AZ 85304 Phone: 623-847-2000 |